Aurobindo Pharma (AUROPHARMA.BO) Earnings Analysis
Aurobindo Pharma (AUROPHARMA.BO) next reports earnings on 2026-08-06, consensus EPS 17.26 INR. Last quarter (2026-05-20) it missed with EPS 15.86 INR vs 16.33 INR est (-2.9%). It has beaten estimates in 0/7 recent quarters (0%). Trailing P/E 25.16.
Last updated 2026-07-23 · Source: FMP fundamentals + earnings calendar (company filings); consensus from sell-side analyst grades
When does AUROPHARMA.BO next report earnings?
| Next earnings date | 2026-08-06 |
|---|---|
| Consensus EPS estimate | 17.26 INR |
| Revenue estimate | 90.06B |
AUROPHARMA.BO earnings history — beats and misses
| Quarter (report date) | EPS actual | EPS est. | Surprise | Result |
|---|---|---|---|---|
| 2026-05-20 | 15.86 INR | 16.33 INR | -2.9% | Miss |
| 2026-02-09 | 15.67 INR | 15.94 INR | -1.7% | Miss |
| 2025-08-03 | 14.2 INR | 16.68 INR | -14.9% | Miss |
| 2025-05-26 | 15.56 INR | 17.57 INR | -11.4% | Miss |
| 2025-02-06 | 14.56 INR | 15.54 INR | -6.3% | Miss |
| 2024-11-08 | 14 INR | 16.05 INR | -12.8% | Miss |
| 2024-08-11 | 15.69 INR | 16.2 INR | -3.1% | Miss |
Beat rate: 0/7 (0%) over reported quarters with consensus data.
AUROPHARMA.BO valuation and analyst view
| Trailing P/E | 25.16 |
|---|---|
| Trailing EPS | 60.336 INR |
| Price / book | 2.33 |
| Dividend yield | 0.26% |
| Market cap | 880.61B |
Limited or no published sell-side analyst coverage for this symbol.
Related research pages
Frequently asked questions
When is Aurobindo Pharma (AUROPHARMA.BO)'s next earnings date?
Aurobindo Pharma is next scheduled to report on 2026-08-06, with a consensus EPS estimate of 17.26 INR and revenue estimate of 90.06B.
Did AUROPHARMA.BO beat earnings last quarter?
In its 2026-05-20 report, AUROPHARMA.BO posted EPS of 15.86 INR versus a 16.33 INR estimate — a miss of 2.9%.
What is AUROPHARMA.BO's earnings track record?
Over the last 7 reported quarters with consensus data, AUROPHARMA.BO beat estimates 0 times (0%).
What is AUROPHARMA.BO's current P/E ratio and EPS?
AUROPHARMA.BO trades at a trailing P/E of 25.16 on trailing EPS of 60.33604765265894 INR.
What do analysts rate AUROPHARMA.BO?
AUROPHARMA.BO has limited or no published sell-side analyst coverage in our dataset, so no consensus rating is shown. Fundamentals and earnings history above are sourced from company filings via FMP.